Testosterone therapy is recommended in men with hypogonadism to correct symptoms of testosterone deficiency. Men who are otherwise healthy do not need to be screened for hypogonadism.
Long-term treatment with testosterone undecanoate was associated with reduced cardiovascular morbidity and mortality in patients with hypogonadism and type 2 diabetes.
In a subanalysis, researchers discovered that testosterone deficiency was common in men with a sustained virologic response after being treated for hepatitis C.
Testosterone replacement therapy prevents further bone loss at the lumbar and femoral levels in patients with congenital hypogonadotropic hypogonadism, but it does not reliably elevate bone mineral density out of the osteopenic/osteoporotic range.
The Food and Drug Administration (FDA) has approved Jatenzo (testosterone undecanoate; Clarus Therapeutics) capsules for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: congenital or acquired primary hypogonadism or hypogonadotropic hypogonadism.
Despite research suggesting that there may be increased cardiovascular risk from off-label prescription testosterone use, usage in men with coronary artery disease remains higher than in men without coronary artery disease.
Investigators examine total testosterone, free testosterone, and sex hormone binding globulin levels in pregnant women in the third trimester with PCOS.
